ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $2.7M invested in ProShares UltraShort NASDAQ Biotechnology in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
1.34% less ownership
Funds ownership: 17.58% → 16.24% (-1.3%)
11% less funds holding
Funds holding: 9 → 8 (-1)
34% less capital invested
Capital invested by funds: $4.07M → $2.7M (-$1.38M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$515K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$124K |
| 3 |
HF
HRT Financial
New York
|
+$56.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$8.75K |
| 5 |
Morgan Stanley
New York
|
+$2.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$782K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$100K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.3K |
BIS Hedge Fund Activity: Q4 2019 in Review
8 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2019, worth a combined $2.7M — down 34% from $4.07M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was WealthSource Partners, adding an estimated $515K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $782K sold.
- 8 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2019, down from 9 in Q3 2019.
- Funds reported $2.7M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2019, down 34% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2019 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2019 was WealthSource Partners, an estimated $515K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2019 was Susquehanna International Group, an estimated $782K sold.
Based on aggregated 13F filings for Q4 2019.